Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMM58JY)

Drug Name
Ziprasidone Drug Info
Synonyms
146939-27-7; Geodon; Zeldox; Ziprasidone hydrochloride; Ziprasidone [INN:BAN]; UNII-6UKA5VEJ6X; CP 88059; Ziprasidone mesylate trihydrate; 6UKA5VEJ6X; CHEMBL708; C21H21ClN4OS; CHEBI:10119; CP-88,059-1; ziprazidone; DSSTox_CID_3753; DSSTox_RID_77186; 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one; DSSTox_GSID_23753; ziprasidonum; ziprasidona; 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one; Geodon; Zipradon; Ziprasidona; Ziprasidonum; Ziprazidone; CP 88059-01; Geodon (TN); Zeldox (TN); Zipradon (TN); Ziprasidone (INN); CP-88,059; CP-88059-1; CP-88,059-01; 5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 6-chloro-5-[2-[4-(7-thia-8-azabicyclo[430]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one; TC-5280
Therapeutic ClassAntipsychotic Agents
Cross-matching ID
PubChem CID
60854
ChEBI ID
CHEMBL708
CAS Number
CAS 146939-27-7
TTD Drug ID
D0R1JV
VARIDT Drug ID
DR00810
INTEDE Drug ID
DR1732
ACDINA Drug ID
D00742

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Proteasome 2.38 0.00e+0 44/46 (95.65%) PSMA4;PSMA7;PSMC6;...
Intestinal immune network for IgA production 2.14 0.00e+0 38/48 (79.17%) CD40;HLA-DQA1;HLA-DQB1;...
Parkinson disease 2.08 0.00e+0 176/249 (70.68%) TXN;MAP3K5;PSMA4;...
Terpenoid backbone biosynthesis 1.93 9.68e-3 18/22 (81.82%) HMGCR;IDI1;ACAT2;...
Antigen processing and presentation 1.92 7.74e-3 60/78 (76.92%) HSPA8;HSPA1A;IFI30;...
Steroid biosynthesis 1.88 1.29e-2 19/20 (95%) MSMO1;SC5D;DHCR7;...
Porphyrin and chlorophyll metabolism 1.87 1.11e-2 23/43 (53.49%) HMOX1;UGT2A3;HMBS;...
Ferroptosis 1.85 1.29e-2 36/41 (87.8%) HMOX1;TFRC;FTH1;...
Asthma 1.81 2.15e-2 25/31 (80.65%) CD40;HLA-DQA1;HLA-DQB1;...
Prion disease 1.81 1.94e-2 209/273 (76.56%) CAV2;HSPA8;HSPA1A;...
Collecting duct acid secretion 1.80 2.11e-2 22/27 (81.48%) CA2;ATP6V1A;ATP6V1B2;...
Folate biosynthesis 1.79 2.04e-2 23/26 (88.46%) AKR1C3;MOCOS;PTS;...
Thiamine metabolism 1.77 2.18e-2 12/15 (80%) AK4;AK1;TPK1;...
Pancreatic secretion 1.76 2.21e-2 87/102 (85.29%) CA2;GNAS;KCNMA1;...
Glutathione metabolism 1.75 2.15e-2 43/57 (75.44%) CHAC1;ANPEP;GCLM;...
Cardiac muscle contraction 1.74 2.66e-2 64/87 (73.56%) ACTC1;MYL4;TPM4;...
Systemic lupus erythematosus 1.72 2.81e-2 45/135 (33.33%) CD40;HLA-DQA1;HLA-DQB1;...
Oxidative phosphorylation 1.72 2.65e-2 93/133 (69.92%) ATP5F1C;SDHB;NDUFA6;...
Bacterial invasion of epithelial cells 1.72 2.78e-2 59/77 (76.62%) CAV2;CAV1;MET;...
Fatty acid elongation 1.68 3.87e-2 19/27 (70.37%) ELOVL6;HACD1;HACD3;...
Biosynthesis of unsaturated fatty acids 1.68 3.69e-2 21/27 (77.78%) SCD;FADS1;ELOVL6;...
Spinocerebellar ataxia 1.65 4.57e-2 128/143 (89.51%) MAP3K5;PSMA4;CYCS;...
Tryptophan metabolism 1.65 4.43e-2 35/42 (83.33%) ACAT2;IDO1;DLD;...
Autoimmune thyroid disease 1.65 4.41e-2 46/53 (86.79%) CD40;HLA-DQA1;HLA-DQB1;...
Linoleic acid metabolism 1.64 4.54e-2 21/29 (72.41%) PLA2G4A;PLAAT3;PLA2G12A;...
Viral myocarditis 1.64 4.42e-2 53/60 (88.33%) CD40;CAV1;HLA-DQA1;...
Amyotrophic lateral sclerosis 1.63 4.78e-2 267/364 (73.35%) MAP3K5;PSMA4;CYCS;...
Cysteine and methionine metabolism 1.62 4.75e-2 43/50 (86%) GCLM;DNMT3B;GOT1;...
Protein processing in endoplasmic reticulum 1.61 4.85e-2 127/171 (74.27%) RAD23B;HSPA8;HSPA1A;...
Nitrogen metabolism 1.61 4.79e-2 16/17 (94.12%) CA2;CA9;CA12;...
Notch signaling pathway -1.96 0.00e+0 49/59 (83.05%) ADAM17;TLE4;RFNG;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H